Phase II Study of Alimta (Pemetrexed) Treatment of Advanced Thymoma and Thymic Carcinoma
The broad range of clinical activity of thymic carcinomas makes the likelihood of detecting
efficacy of a single agent such as premetrexed a reasonable objective since these
malignancies are relatively slow growing and exhibit a broad range of chemosensitivity to
Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
to determine the objective response rate of premetrexed in previously treated patients with thymoma or thymic carcinoma.
baseline, after 2 cycles, then q 6wks
Patrick Loehrer, M.D.
United States: Institutional Review Board
|Indiana University Cancer Center||Indianapolis, Indiana 46202-5265|